Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

PURPOSE: Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. However, there are conflicting findings regarding the potential benefit of adjuvant EGFR-TKI in patients with lung cancer harboring E...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Oxnard, Geoffrey R., Janjigian, Yelena Y., Arcila, Maria E., Sima, Camelia S., Kass, Samantha L., Riely, Gregory J., Pao, William, Kris, Mark G., Ladanyi, Marc, Azzoli, Christopher G., Miller, Vincent A.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186869/
https://ncbi.nlm.nih.gov/pubmed/21831955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1080
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares